Document Detail

Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking.
MedLine Citation:
PMID:  22117079     Owner:  NLM     Status:  MEDLINE    
Resistance to cisplatin (CDDP)-based therapy is a major hurdle to the successful treatment of human ovarian cancer (OVCA), and the chemoresistant phenotype in OVCA cells is associated with Akt-attenuated p53-mediated apoptosis. Pro-apoptotic functions of p53 involve both transcription-dependent and -independent signaling pathways, and dysfunctional localization and/or inactivation of p53 contribute to the development of chemoresistance. PARC is a cytoplasmic protein regulating p53 subcellular localization and subsequent function. Little is known about the molecular mechanisms regulating PARC. Although PARC contains putative caspase-3 cleavage sites, and CDDP is known to induce the activation of caspases and calpains and induce proteasomal degradation of anti-apoptotic proteins, if and how PARC is regulated by CDDP in OVCA are unknown. Here, we present evidence that CDDP promotes calpain-mediated PARC down-regulation, mitochondrial and nuclear p53 accumulation, and apoptosis in chemosensitive but not resistant OVCA cells. Inhibition of Akt is required to sensitize chemoresistant cells to CDDP in a p53-dependent manner, an effect enhanced by PARC down-regulation. CDDP-induced PARC down-regulation is reversible by inhibition of calpain but not of caspases or the 26 S proteasome. Furthermore, in vitro experiments confirm the ability of calpain in mediating Ca(2+)-dependent PARC down-regulation. The role of Ca(2+) in PARC down-regulation was further confirmed as ionomycin-induced PARC down-regulation in both chemosensitive and chemoresistant ovarian cancer cells. The data presented here implicate the regulation of p53 subcellular localization and apoptosis by PARC as a contributing factor in CDDP resistance in OVCA cells and Ca(2+)/calpain in PARC post-translational processing and chemosensitivity.
Michael G Woo; Kai Xue; Jiayin Liu; Heidi McBride; Benjamin K Tsang
Related Documents :
22005259 - Nf-κb, jnk and p53 pathways are involved in tubeimoside-1-induced apoptosis in hepg2 c...
790889 - Human auto-immune thyroiditis.
7160339 - Evidence for cellular mediated immunity in an animal model of autoimmune pituitary dise...
8742119 - Growth hormone and the immune response to bacterial infection.
19656309 - Inflammatory effects of nutritional stimuli: further support for the need for a big pic...
21743969 - Notch-1 activation-dependent p53 restoration contributes to resveratrol-induced apoptos...
17966399 - Rankl inhibition: from mice to men (and women).
22643849 - Loss of mucosal cd103+ dcs and il-17+ and il-22+ lymphocytes is associated with mucosal...
7821219 - Fgf2 regulates proliferation of neural crest cells, with subsequent neuronal differenti...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-11-23
Journal Detail:
Title:  The Journal of biological chemistry     Volume:  287     ISSN:  1083-351X     ISO Abbreviation:  J. Biol. Chem.     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-02-06     Completed Date:  2012-03-25     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  2985121R     Medline TA:  J Biol Chem     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3963-75     Citation Subset:  IM    
Reproductive Biology Unit and Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, Ontario K1Y 4E9, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology
Apoptosis / drug effects,  genetics
Calcium / metabolism
Calcium Ionophores / pharmacology
Calpain / genetics,  metabolism*
Carrier Proteins / genetics,  metabolism*
Caspase 3 / genetics,  metabolism
Cell Line, Tumor
Cisplatin / pharmacology
Down-Regulation / drug effects,  genetics
Drug Resistance, Neoplasm*
Enzyme Activation / drug effects,  genetics
Gene Expression Regulation, Neoplastic*
Ionomycin / pharmacology
Ovarian Neoplasms / drug therapy,  genetics,  metabolism*,  pathology
Proteasome Endopeptidase Complex / genetics,  metabolism
Protein Processing, Post-Translational*
Protein Transport / drug effects
Tumor Suppressor Protein p53 / genetics,  metabolism*
Grant Support
MOP-15691//Canadian Institutes of Health Research
Reg. No./Substance:
0/Antineoplastic Agents; 0/Calcium Ionophores; 0/Carrier Proteins; 0/H7-AP1 protein, human; 0/TP53 protein, human; 0/Tumor Suppressor Protein p53; 15663-27-1/Cisplatin; 56092-81-0/Ionomycin; 7440-70-2/Calcium; EC 3.4.22.-/CASP3 protein, human; EC 3.4.22.-/Calpain; EC 3.4.22.-/Caspase 3; EC Endopeptidase Complex; EC 3.4.99.-/ATP dependent 26S protease

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Streptococcus pyogenes in human plasma: adaptive mechanisms analyzed by mass spectrometry-based prot...
Next Document:  Parents' views and experiences of childhood obesity management in primary care: a qualitative study.